El Hassani Taib Hajar, Hamada Syrine, El Moustaoui Meryem, Ammar Najoua, Ismaili Nadia, Benzekri Laila, Meziane Mariame
Dermatology Department, Ibn Sina University Hospital Center, Mohammed V University, Rabat, MAR.
Cureus. 2025 Aug 18;17(8):e90407. doi: 10.7759/cureus.90407. eCollection 2025 Aug.
Scleromyxoedema (SM) is a rare cutaneous mucinosis characterised by waxy papules, diffuse skin induration, and systemic involvement such as gastrointestinal, cardiopulmonary, or neurological complications. The disease is strongly linked to the presence of monoclonal gammopathy. Traditionally, thyroid dysfunction is considered an exclusion criterion for the diagnosis of SM; however, clinical observations suggest that this association may occur in certain cases. We present the case of a 70-year-old woman with a history of hypothyroidism on levothyroxine for three months, who presented with progressive cutaneous sclerosis affecting the face, trunk, and limbs, along with dysphagia for solid food. Clinical examination revealed generalised induration of the skin and limited mouth opening. Skin biopsy confirmed the diagnosis of SM, revealing fibroblast proliferation and mucin deposition. Laboratory tests identified a monoclonal immunoglobulin G kappa gammopathy, elevated free kappa light chains, and persistent hypothyroidism with high levels of anti-thyroid peroxidase antibodies, which confirmed the diagnosis of Hashimoto's thyroiditis. Liver abnormalities and biopsy findings were consistent with primary biliary cholangitis. The patient was treated with systemic corticosteroids and intravenous immunoglobulin (IVIG), but no clinical improvement was observed. The disease progressed, and she died five months after the last treatment cycle. This case illustrates the rare coexistence of SM and autoimmune thyroid disease, raising questions about whether thyroid dysfunction should systematically exclude SM diagnosis. The differential diagnosis with hypothyroid myxedema and systemic sclerosis is crucial, as their histopathological features differ significantly. Although IVIG is first-line therapy for SM and achieves good response rates in many cases, therapeutic failure, as seen here, highlights the need for further research into optimal treatment strategies for SM with overlapping autoimmune conditions.
硬化性黏液水肿(SM)是一种罕见的皮肤黏蛋白病,其特征为蜡样丘疹、皮肤弥漫性硬结以及胃肠道、心肺或神经等系统受累并出现并发症。该疾病与单克隆丙种球蛋白病密切相关。传统上,甲状腺功能障碍被视为SM诊断的排除标准;然而,临床观察表明,在某些情况下可能会出现这种关联。我们报告一例70岁女性病例,该患者服用左甲状腺素治疗甲状腺功能减退已有三个月,出现累及面部、躯干和四肢的进行性皮肤硬化,以及固体食物吞咽困难。临床检查发现皮肤普遍硬结,张口受限。皮肤活检确诊为SM,显示成纤维细胞增殖和黏蛋白沉积。实验室检查发现单克隆免疫球蛋白Gκ型丙种球蛋白病、游离κ轻链升高,以及伴有高水平抗甲状腺过氧化物酶抗体的持续性甲状腺功能减退,这证实了桥本甲状腺炎的诊断。肝脏异常及活检结果与原发性胆汁性胆管炎一致。患者接受了全身糖皮质激素和静脉注射免疫球蛋白(IVIG)治疗,但未观察到临床改善。疾病进展,在最后一个治疗周期五个月后患者死亡。该病例说明了SM与自身免疫性甲状腺疾病罕见的共存情况,引发了关于甲状腺功能障碍是否应系统性排除SM诊断的疑问。与甲状腺功能减退性黏液水肿和系统性硬化症的鉴别诊断至关重要,因为它们的组织病理学特征有显著差异。尽管IVIG是SM的一线治疗方法,在许多病例中能取得良好的有效率,但如此处所见的治疗失败凸显了对伴有重叠自身免疫性疾病的SM最佳治疗策略进行进一步研究的必要性。